NCT02603172View on ClinicalTrials.gov

A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 12, 2016

Primary Completion Date

May 10, 2017

Study Completion Date

May 10, 2017

Conditions

Amyloidosis

Interventions

DRUG

GSK3039294

GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge